Vivus Study Finds Significant Improvements in Patients with Obstructive Sleep Apnea Treated With Phentermine And Topiramate Extended-Release Capsules
VIVUS (NASDAQ: VVUS) today announced that a study published in the journal SLEEP (2012; 35(11):1529-1539) found that patients with moderate to severe obstructive sleep apnea (OSA) taking phentermine and topiramate extended-release capsules achieved significant improvements in key measures of OSA and cardiovascular risk factors along with weight loss during the 28-week trial.
OSA is a chronic and potentially serious sleep disorder in which breathing is abnormally shallow ("hypopnea") or stops altogether ("apnea") for at least 10 seconds. These repetitive events are associated with collapse of the upper airway during sleep, and may occur 5 to 30 or more times per hour. Although many cases are unrecognized, symptoms may include snoring, fatigue or sleepiness during the day.
OSA afflicts approximately 3% to 7% of the U.S. population. Data from the Wisconsin Cohort Study indicate that the prevalence of OSA in people aged 30-60 years is 9-24% for men and 4-9% for women.
OSA is associated with an increased risk of hypertension, cardiovascular disease, myocardial infarction, stroke and increased mortality.
The current standard of care treatment for OSA is "positive airway pressure" (PAP) in which the upper airway is kept open by increased air pressure, but PAP